Search Within

Tracy B Smart-Curley

Formats
  1. Journal Article (42)
  2. Meeting Abstract (25)
  3. Conference Paper (2)
  4. Review (1)
Groups
  1. Nursing (70)
  2. Department of Medicine (62)
  3. Genitourinary Oncology Service (62)
  4. Solid Tumor Oncology Division (62)
  5. Radiology, Department of (28)
  6. Hematologic Malignancies, Division of (25)

More Groups

People
  1. Howard Scher (58)
  2. Susan Slovin (25)
  3. William Kelly (23)
  4. Michael Morris (19)
  5. Anthony De La Cruz (15)
  6. Lawrence Schwartz (14)

More People

Years
  1. 2024 (3)
  2. 2023 (1)
  3. 2022 (1)
  4. 2021 (1)
  5. 2020 (1)
  6. 2018 (1)

More Years

Publications
  1. Journal of Clinical Oncology (26)
  2. Clinical Cancer Research (8)
  3. Cancer (4)
  4. Proceedings of the American Association for Cancer Research Annual Meeting (4)
  5. Investigational New Drugs (3)
  6. Oncology Nursing Forum (3)

More Publications

Publishers
  1. American Society of Clinical Oncology (26)
  2. American Association for Cancer Research (14)
  3. Elsevier Science, Inc. (5)
  4. Springer (5)
  5. Wiley Blackwell (5)
  6. Oncology Nursing Society (ONS) (4)

More Publishers

Results (70)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Prostate cancer patients with personal and family history of major adverse cardiovascular events (mace) have higher risk of mace after beginning androgen deprivation therapy
    Meeting Abstract

    Curley, T.; Atkinson, S. N.; Boldt-Houle, D. M.; Daugherty, R.; Liebertz, C.
    Oncology Nursing Forum (2024)

    Fulltext@MSK | Save
  • Phase 1b study of enzalutamide plus CC-115, a dual mTORC1/2 and DNA-PK inhibitor, in men with metastatic castration-resistant prostate cancer (mCRPC)
    Journal Article

    Zhao, J. L.; Antonarakis, E. S.; Cheng, H. H.; George, D. J.; Aggarwal, R.; Riedel, E.; Sumiyoshi, T.; Schonhoft, J. D.; Anderson, A.; Mao, N.; more...
    British Journal of Cancer (2024)

    Fulltext@MSK | Save
  • A proposal for the comprehensive care of men on androgen deprivation therapy: Recommendations from the Multidisciplinary Prostate Cancer 360 Working Group
    Review

    Crawford, E. D.; Garnick, M. B.; Eckel, R. H.; Miner, M. M.; Freedland, S. J.; Pachynski, R. K.; Wassersug, R. J.; Rosenberg, M. T.; Walker, L. M.; Fairman, C.; more...
    Urology Practice (2024)

    Fulltext@MSK | Save
  • Randomized phase II multicenter trial of abiraterone acetate with or without cabazitaxel in the treatment of metastatic castration-resistant prostate cancer
    Journal Article

    Slovin, S. F.; Knudsen, K.; Halabi, S.; de Leeuw, R.; Shafi, A.; Kang, P.; Wolf, S.; Luo, B.; Gopalan, A.; Curley, T.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Effects of niraparib on health-related quality of life in the final analysis of the GALAHAD study in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations
    Meeting Abstract

    Tran, M.; Olivier, K.; Liu, Y.; Bevans, K. B.; Mason, G. E.; Curley, T.
    Oncology Nursing Forum (2022)

    Fulltext@MSK | Save
  • A phase Ib study of enzalutamide (Enza) plus CC-115 in men with metastatic castration-resistant prostate cancer (mCRPC)
    Meeting Abstract

    Zhao, J. L.; Antonarakis, S.; Cheng, H.; George, D. J.; Aggarwal, R. R.; Abida, W.; Decker, B.; Smart-Curley, T.; Schonhoft, J.; Anderson, A.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • Evaluation of immune-related adverse events (irAE): Utilizing the patient-reported outcomes of the common terminology criteria for adverse events (PRO-CTCAE) in a phase II study of ipilimumab (ipi) in men with castration-sensitive prostate cancer (CSPC)
    Meeting Abstract

    Vargas Pivato de Almeida, D.; Anderson, J.; Danila, D. C.; Morris, M. J.; Slovin, S. F.; Abida, W.; Dayan, E. S.; Curley, T.; Arauz, G.; Baser, R. E.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • A phase II study of the dual mTOR inhibitor MLN0128 in patients with metastatic castration resistant prostate cancer
    Journal Article

    Graham, L.; Banda, K.; Torres, A.; Carver, B. S.; Chen, Y.; Pisano, K.; Shelkey, G.; Curley, T.; Scher, H. I.; Lotan, T. L.; more...
    Investigational New Drugs (2018)

    Fulltext@MSK | Save
  • Exploring the role of RB and AR in a phase II randomized multicenter trial of abiraterone acetate with or without cabazitaxel in metastatic castration resistant prostate cancer (mCRPC)
    Meeting Abstract

    Slovin, S. F.; Knudsen, K. E.; Carbone, E.; Showunmi, A.; Hullings, M.; Morris, M. J.; Autio, K. A.; Kampel, L. J.; Molina, A. M.; Chen, Y.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • A phase 1/2 study combining ipilimumab with abiraterone acetate plus prednisone in chemotherapy- and immunotherapy-naive patients with progressive metastatic castration resistant prostate cancer (mCRPC)
    Meeting Abstract

    Danila, D. C.; Kuzel, T.; Cetnar, J. P.; Rathkopf, D. E.; Morris, M. J.; Alumkal, J. J.; Butler, A.; Curley, T.; Hullings, M.; Buddle, J. R.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save